Trelegy Ellipta Reduces COPD Exacerbations, Improves Lung Function and Quality of Life, Trial Shows

Trelegy Ellipta Reduces COPD Exacerbations, Improves Lung Function and Quality of Life, Trial Shows

Treatment with the triple-combination therapy Trelegy Ellipta reduced exacerbations in chronic obstructive pulmonary disease (COPD) and improved patients’ lung function and quality of life, according to a Phase 3 trial.

The Phase 3 IMPACT study compared Trelegy to other common COPD medications in 10,355 patients in 37 countries, according to GlaxoSmithKline (GSK) and Innoviva.

Findings from the study, titled “Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD,” were recently published in the New England Journal of Medicine.

Trelegy Ellipta was approved as a maintenance treatment for patients with COPD in both the U.S. and the E.U. in 2017.

The treatment, marketed by GSK, contains the inhaled corticosteroid fluticasone furoate, the long-acting muscarinic antagonist umeclidinium, and the long-acting beta2-adrenergic agonist (LABA) vilanterol.

A dose of Trelegy contains 100 micrograms (mcg) of fluticasone furoate, 62.5 mcg of umeclidinium, and 25 mcg of vilanterol.

The IMPACT study (NCT02164513) compared Trelegy Ellipta with GSK’s once-daily COPD therapies Breo Ellipta (fluticasone furoate/vilanterol) and Anoro Ellipta (umeclidinium/vilanterol). All three treatments were delivered in the same dose and inhaler.

Patients enrolled in the trial had moderate to very severe COPD and a history of exacerbations in the previous 12 months. The trial’s more than 10,000 patients were from 1,035 study centers globally.

Results revealed that treatment with the triple therapy Trelegy Ellipta significantly reduced the number of COPD hospitalizations due to severe exacerbations by 34% compared to Anoro Ellipta. Compared to Breo Ellipta, the reduction was of 13%, but this difference was not statistically significant.

The data also showed that Trelegy and Breo, the two medications containing the corticosteroid fluticasone furoate, lowered the risk of on-treatment mortality compared to Anoro.

Specifically, Trelegy decreased this risk by 42.1% compared to Anoro. However, off-treatment data should be analyzed to fully understand the benefits in mortality risk, the team emphasized.

Results further revealed improvements in other clinically relevant parameters, including lung function and health-related quality of life. Additional results will be presented at future scientific meetings.

“Reducing exacerbations to keep patients out of hospital is a key goal of COPD management alongside improving lung function and quality of life,” Dave Allen, head of Respiratory Therapy Area Research and Development at GSK, said in a press release. “The IMPACT study shows how Trelegy Ellipta can help patients with a history of exacerbation achieve these goals.”

Ted Witek, senior vice president and chief scientific officer at Innoviva, said that the “role of inhaled corticosteroids (ICS) in COPD have long been debated, and this landmark trial provides further evidence of their benefit in the population studied and compelling data towards clarifying the role of ICS containing regimens in the COPD treatment paradigm.”

The trial also showed that Trelegy had a similar safety profile as its individual components. Among the most frequent adverse events in the study were viral upper respiratory tract infection, COPD worsening, pneumonia, and headache.

In February 2018, GSK and Innoviva submitted results from the IMPACT study to the European Medicines Agency to support the label expansion of Trelegy Ellipta for European patients with moderate to severe COPD who are at risk of an exacerbation and require triple therapy. A similar submission was filed in the U.S.

José is a science news writer with a PhD in Neuroscience from Universidade of Porto, in Portugal. He has also studied Biochemistry at Universidade do Porto and was a postdoctoral associate at Weill Cornell Medicine, in New York, and at The University of Western Ontario in London, Ontario, Canada. His work has ranged from the association of central cardiovascular and pain control to the neurobiological basis of hypertension, and the molecular pathways driving Alzheimer’s disease.
José is a science news writer with a PhD in Neuroscience from Universidade of Porto, in Portugal. He has also studied Biochemistry at Universidade do Porto and was a postdoctoral associate at Weill Cornell Medicine, in New York, and at The University of Western Ontario in London, Ontario, Canada. His work has ranged from the association of central cardiovascular and pain control to the neurobiological basis of hypertension, and the molecular pathways driving Alzheimer’s disease.
Latest Posts
  • Fasenra add-on
  • ensifentrine
  • autoimmune responses, COPD
  • TLD therapy for COPD
Print Friendly, PDF & Email


    • beverly mcinerney says:

      I agree – took it for a month and had all the side effect symptoms – chronic pain, headache, chronic cough – I felt awful. Thought I had the flu.

  1. Doug Brown says:

    What average person can afford this price. You people need to realize that we live from pay day to pay day. You would sell a lot more by making it available to all that need it. But because of your greed people have to go without medicine that helps them survive. One day you greedy bastards will have to answer for it all.

    • Barbara Solenick says:

      I am on medicare and my insurance co. has not approved this (yet). it was going to cost over $300 (I think). the ins. co. approved it for me but it was still going to be about $100. I go to the doctor in a month’s time and will get her to approve another ellipta product (Breo?) similar I think. then I will be a mail order supply to cut down the cost to about $25/mth. but for this month waiting for my appt., I would rather not be able to breathe, than to pay $100 for Trilegy. I can’t afford it. there is a coupon you can find, but it excludes people on Medicare. with the coupon, it would cost $10. the whole drug industry has made it impossible to live comfortably for the average person. now Trump is talking about the drug industry. God Bless….

    • Sandy says:

      This worked great for me. Now, I can no longer afford this so when I told my dr. I’m not going to take it anymore they gave me enough sample packs to get me thru the end of the year. After that I have no clue what I’m going to do. For now I’m looking into changing insurance co. It’s all so disgusting!!!!

  2. John Polachek says:

    In Shanghai China they made have thin Bronchi, grown alveoli, by using SOX9+BCs stem cells. There are 15 people that now can breathe almost normally. We will see it here when FDA and big pharma makes all their monies.You can google and read but it will just show, what bastards we have in our medical community.

  3. George Glassner says:

    Have there been any test to compare the two medications I take, Spiriva Resprimat, and Symbicort to your new medication Trelegy Ellipta?

  4. Paul E Rawlins says:

    After experiencing no effect from different inhalers, my doctor recommended Trelegy. My breathing has improved along with my energy level throughout the day. (no side effects after 14 days of use)

      • Brenda Wells says:

        Did it take five weeks for you to see an improvement?
        I started on trelegy but find that it works ok, i just feel short of breath. Been on it three weeks.

    • Ramona says:

      Hi, Paul. It is good to hear your results. I’ve been taking Stiolto and not much results but tomorrow I will start Trelegy. I am hoping for the best.

  5. Pulmonologist gave me a 1-month’s supply of Trelegy. My breathing improved, I had more energy and actually was able to sleep. Trelegy was wonderful for me but WellCare does not cover this drug in Georgia. I’m on a medicare health plan therefore, I do not qualify for the low cost for this drug. I have tried to find an affordable way to purchase this drug out-of-pocket but even with coupons and discounts, it is almost $300 monthly. I cannot afford it. What are we to do?

    • Shala says:

      Have you heard of the RX discount card? I have one and I used it for a cream for my face that my Medicare and/or Tri-Care would not cover. The cost would have been 80.00 but I got the script for 39.00 at, of all places, Walmart. The one I used is called GoodRx. You can call and request a card at1-844-292-1232. Another one is called Pharmacy Savings Card, Singlecare and you can reach them at 1-844-234-3135.

  6. Michael says:

    I was prescribed Breo. Here in Louisiana ti is $800 a month without insurance so can someone tell me how to get it for $300

    • Karen Richard says:

      I am on Breo as well. Go to and print out the coupon. I pay $10.00 a month and without the coupon the insurance would make me pay 69.00.

  7. Susan Lagrone says:

    Trelegy has been working great for me. I feel like I can get up and move without losing my breath!! I also loved Breo but felt like I hit a plateau and could not get more improvement. With my Wellcare Medicare prescription coverage part D, and a Wellcare “additional help” program, I get the Breo or the Trelegy for about an $8.00 copay per month. Without the medicare prescription Part D, my Breo was over $300.00. Please call your insurance companies and let them help you get on the coverage plan your health requires.

  8. Barrie Chapman says:

    I have just started to use Trelogy so we will see how it goes. COPD a nasty thing give to those who suffer from it by society itself. Yes, smoking does contribute however is not the main cause, look at the air everyone breaths. Diesel fumes Co3 fumes dirt dust pollens and the list goes on Maybe governments should clean their act up and clean the air up . no one asked for it so I believe strongly medications to treat this should be supplied free of cost to any sufferer.

    • Geno says:

      My COPD is caused by Asbestosis. It’s as debilitating as Mesothelioma but not as fatal. The average mortality of a person from the first signs of Mesothelioma is less than 12 months. Asbestosis patients can experience the same symptoms but live for many years.
      Most of us contracted these diseases through no fault of our own and many will either die or spend their life feeling like they’re drowning because they cannot afford the treatment and medications.
      Being so out of breath that you cannot walk ten feet or sleep for more than an hour at a time is worse than death.
      I wish every Senator and Congress person had to experience this life for 30 days.
      Things would by god change then!

  9. I took Trilogy for a week but my heart raced so hard 24/7 that I thought it would stopso I stopped taking it but it did help the breating so much more I do have heart failure could that be the cause?Great Medicane though for breathing.Thank you Kathleen Janus

  10. J says:

    Trelegy Ellipta is just another VERY high priced bullshit product by GSK. I was on Advair – also by GSK; my doctor thought it might be a good idea for me to try Trelegy (doctor is probably getting a kick back from GSK)- in any case, or for what its worth- there was really no difference from my use of Advair to Trelegy. However, I did start to experience headaches and extremely dry skin and shortness of breath while on Trelegy- The price is ridiculously HIGH- that is because you are paying for GSK’s research and development and product marketing and licensing. To market such a product to people that may really need and benefit health wise is really disgusting and the Money is the most important factor to the pharmaceutical company. Advair for instance, manufatured by GSK had a patent that was supposed to expire in 2012; which would allow a Generic type to be marketed— low and behold! NOPE–why ??? because their half jerk answer was that they are trying to fabricate a dispenser??? really? but now here come Trelegy by GSK specifically marketed to replace Advair and it is even more expensive; $620.00 for 60 blisters that , by the way , dispense two at a time; and there is no way you can just take one dose because the Trelegy dispenser pops two. So, basically you are dosing twice a day just like with Advair – BUT_ you aren’t suppose to figure that out. Bottom line here: I will not be renewing my script for Trelegy; it’s a waste of money; I am not going to be paying almost $200.00 a month towards the drug cost and maxing out my prescription plan drug coverage in 6 months. I’m also going to look into possibly stopping Advair as well; as GSK needs to be investigated for ripping off the public and using people who are at need to profit and exploit.

    • Kara Lewis says:

      I do believe all research is done by Collage students for free. I have heard this several times. Prices probably do not reflect research and trials.

    • Matt Watson says:

      GSK was fined 3 billion dollars for bribing doctors to push their products. Before the fine 3 months of advair was 990 cash price. The month after the fine it cost 1790 for the 3 month supply. Now my new doctor is pushing Trelegy on me and I have too many side effects.

  11. thomas m koss says:

    amazingly, people simply don’t understand the true expense of R & D, nor -good or bad – we do live under capitalism and profit for workers, shareholders is, of course a corporation’s concern and responsibility. I don’t work for free…

  12. Darlene Luce says:

    After my last exacerbation that almost killed me, my doctor prescribe Trelegy for me. I’m lucky that with my insurance I only pay $10 for it (when I was on Spiriva it costs me $75/month). It has helped me and I have been on it for 2 months. I haven’t had any side effects either.

  13. Charlette F Mellor says:

    I started Trelegy with a 30 day sample from my pulmonologist (02/01/19) and I feel I am breathing much better. I previously took Spiriva and Advair for about 4 years. I just picked up 90 days worth of Trelegy and I am blessed because I have no costs being as I am on Medicare and Tricare for Life. I am hoping Trelegy will be long lasting for me.

  14. Cheryll Bartolotta says:

    The data also showed that Trelegy and Breo, the two medications containing the corticosteroid fluticasone furoate, lowered the risk of on-treatment mortality compared to Anoro?

    My website 0

  15. larry winslow says:

    Been on Trelegy for 60days cant tell any help from it morning are hell and about 1pm for the last week been getting a hoarse voice. Im still working but i can see it coming to an end.Ithink i need to talk to my dr. and go back to symbicort and what ever else.

  16. Chris Lane says:

    I am a Respiratory Specialist in the UK, absolutely shocked to hear that people are going without meds they cant afford. One of the reasons there are so many drugs and devices on the market is that every one is different, different inspiratory flow, technique and response to the drug depending on pathology. I often try several drugs with patients until we find one they are happy with. I will say however that COPD care is moving away from inhaled steroids except for certain subgroups.
    With that said, still shocked that GSK (and other companies is should imagine) inflate the price so much. The cost to the NHS for Trelegy is £22.50 (about $30) – and free to patients. Need to put people above money

  17. Barnie says:

    I currently take Anoro Ellipta with no side effects whatsoever that I’ve noticed. Would it be worth my time and effort to switch to Trelegy Ellipta? I’ve read that there are some better results with Trelegy over Anoro, but is it worth the change since I have no ?

  18. Paul Hughes says:

    I’m in UK and my doctor has suggested I try Trelegy. I am currently taking Symbicort 400 and Spiriva which has been working ok for me although I have recently developed high BP and chest pains which are being looked into. My meds are free so my concern is whether or not there will be any change in performance and side effects. If anyone has made the same change of meds I would appreciate any opinions on making the change or whether I should just stay on my existing script. It’s quite shocking to read through the posts and discover the misery many go through in the U.S. with costs of treatment. Many outside the UK slam out NHS but for us it the greatest achievement a country could wish for, now we are fighting to save it from the greedy wealthy profiteers. Good luck and good health.

  19. Michael Carr says:

    I’m presently using Anoro and am wondering if Trelegy is any better. I have no noticeable side effects from Anoro, but feel it doesn’t last as long as it is suppose to. I’m disabled and I don’t have to pay anything & TG for that because the Anoro cost $402 a month. I also have Albuterol as a rescue inhaler at a price of $49. My Dr has suggested a new lung implant procedure that keeps the airways open. I go for a CT scan the 29th to determine the worst lung lobe. Scary!!

  20. PJ says:

    I am on Breo, I asked the Doc if there is anything new. He gave me a sample of Trelegy. I used it for two days and I had severe dry eye and dry mouth and was miserable. As soon as I stopped it, the symptoms went away Umeclidinnum isa anticholinegic and it is not in Breo or Anora.Just an FYI

Leave a Comment

Your email address will not be published. Required fields are marked *